"After one year of service, we are happy to renew our contract and have
CCG Investor Relations continue to design and execute our investor relations
campaign," said Mr. Senshan Yang, Chief Executive Officer of
"The harmful threat of aflatoxins presents an opportunity for
About China Medicine Corporation
China Medicine Corporation is a leading pharmaceutical company which discovers, develops, and distributes over 2,300 pharmaceutical products in China including prescription and over the counter ("OTC") drugs, traditional Chinese medicine ("TCM") products, herbs and dietary supplements. The Company distributes the products to wholesale distributors in 28 provinces, over 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at http://www.chinamedicinecorp.com . Those who are interested in ADTZ could go to the website and read the white paper under R&D section.
Cautionary Statement
This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
For more information, please contact: Company Contact: Ms. Huizhen Yu Chief Financial Officer China Medicine Corporation Tel: +86-20-8739 1718 Email: konzern08@163.com Investor Relations Contact: Mr. Crocker Coulson President CCG Investor Relations Tel: +1-646-213-1915 (NY Office) Email: crocker.coulson@ccgir.com
SOURCE China Medicine Corporation